Immune Checkpoint Inhibitors in Geriatric Oncology

Cook, Sarah L.; Al Amin, Md; Bari, Shahla; Poonnen, Pradeep J.; Khasraw, Mustafa; Johnson, Margaret O.

doi:10.1007/s11912-024-01528-3

Curr Oncol Rep

2024

DOI: 10.1007/s11912-024-01528-3

|View full text |Cite

Immune Checkpoint Inhibitors in Geriatric Oncology

Sarah L. Cook,

Md Al Amin,

Shahla Bari

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Zhou,

Cai,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Zhou,

Cai,

Lin

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab

Kurnik,

Kolar Kus,

Krepek

et al. 2024

Immunotherapy

View full text Add to dashboard Cite

Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations

Gallus,

Young,

Cook Quackenbush

et al. 2024

Neuro-Oncology

View full text Add to dashboard Cite

Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in patients with malignant gliomas have shown some early promise in pediatric and adult patients. However, the long-term benefits and safety for patients remain to be established. The ultimate success of CAR T-cell therapy for malignant glioma will require the integration of an in-depth understanding of the immunology of the central nervous system (CNS) parenchyma with strategies to overcome the paucity and heterogeneous expression of glioma-specific antigens. We also need to address the cold (immunosuppressive) microenvironment, exhaustion of the CAR T-cells, as well as local and systemic immunosuppression. Here, we discuss the basics and scientific considerations for CAR T-cell therapies and highlight recent clinical trials. To help identify optimal CAR T-cell administration routes, we summarize our current understanding of CNS immunology and T-cell homing to the CNS. We also discuss challenges and opportunities related to clinical trial design and patient safety/monitoring. Finally, we provide our perspective on future prospects in CAR T-cell therapy for malignant gliomas by discussing combinations and novel engineering strategies to overcome immuno-regulatory mechanisms. We hope this review will serve as a basis for advancing the field in a multiple discipline-based and collaborative manner.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Immune Checkpoint Inhibitors in Geriatric Oncology

Cited by 3 publications

References 74 publications

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Toxicity profile of camrelizumab-based immunotherapy in older adults with advanced cancer

Fatal rhabdomyolysis and fulminant myocarditis with malignant arrhythmias after one dose of ipilimumab and nivolumab

Chimeric antigen receptor T-cell therapy in patients with malignant glioma—From neuroimmunology to clinical trial design considerations

Contact Info

Product

Resources

About